Evidence mapPaperPMID 36775767Full record

ReviewAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2023

Milestones on the path to clinical pig organ xenotransplantation.

David K C Cooper, Richard N Pierson

Open access · bronzeAbstract readReview
In one paragraph

Review in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Xenotransplantation: Current Understanding of the Mechanism of Immune-Mediated Injury.Journal of the American Society of Nephrology : JASN · 2025
    Review
  11. Emerging roles for complement in lung transplantation.The Journal of clinical investigation · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Green, Sustainable Nephrology: State of the Art Needs for Education and Implementation.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Review
  16. Review
  17. Review
  18. Current Techniques of Gene Editing in Pigs for Xenotransplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  19. Review
  20. Cytotoxic Responses Mediated by NK Cells and Cytotoxic T Lymphocytes in Xenotransplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David K C CooperCenter for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. Electronic address: dkcooper@mgh.harvard.edu.
Richard N PiersonCenter for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Harvard University · US

Funding

NIAID NIH HHS U01 AI153612NIAID NIH HHS U19 AI090959
6 · The paper itself

Abstract

Progress in pig organ xenotransplantation has been made largely through (1) genetic engineering of the organ-source pig to protect its tissues from the human innate immune response, and (2) development of an immunosuppressive regimen based on blockade of the CD40/CD154 costimulation pathway to prevent the adaptive immune response. In the 1980s, after transplantation into nonhuman primates (NHPs), wild-type (genetically unmodified) pig organs were rejected within minutes or hours. In the 1990s, organs from pigs expressing a human complement-regulatory protein (CD55) transplanted into NHPs receiving intensive conventional immunosuppressive therapy functioned for days or weeks. When costimulation blockade was introduced in 2000, the adaptive immune response was suppressed more readily. The identification of galactose-α1,3-galactose as the major antigen target for human and NHP anti-pig antibodies in 1991 allowed for deletion of expression of galactose-α1,3-galactose in 2003, extending pig graft survival for up to 6 months. Subsequent gene editing to overcome molecular incompatibilities between the pig and primate coagulation systems proved additionally beneficial. The identification of 2 further pig carbohydrate xenoantigens allowed the production of 'triple-knockout' pigs that are preferred for clinical organ transplantation. These combined advances enabled the first clinical pig heart transplant to be performed and opened the door to formal clinical trials.

Indexed as

GalactoseGraft RejectionAnimalsAnimals, Genetically ModifiedComplement System ProteinsGraft SurvivalHumansPrimatesTransplantation, HeterologousComplement System ProteinsGalactoseclinical trialgenetically engineeredheartkidneynonhuman primatepigxenotransplantation

Identifiers

PMID36775767
PMCPMC10127379
OpenAlexW4319997944

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.